Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Epoetin alfa with oral versus intravenous iron supplementation in iron-deficient anemic patients with solid tumors receiving non-platinum chemotherapy
NL-OMON26767Active, not recruiting
- Sponsor
- Amsterdam UMC, location VUmc
- Start
- Feb 2001
- Modality
- Recombinant Proteins and Enzymes, Small Molecules
- Countries
- 1
01
Overview
Randomised, open-label trial of epoetin alfa, iron sucrose and ferrous fumarate in anaemia, iron deficiency anemia (IDA) and Non-hematologic malignancy (2 arms), sponsored by Amsterdam UMC, location VUmc. Primary endpoint: Increase in hemoglobin. Started Feb 2001; status: active, not recruiting.
02
Drugs
epoetin alfairon sucroseferrous fumarate
03
Conditions
anaemiairon deficiency anemia (IDA)Non-hematologic malignancy
Beyond the preview
Go deeper on NL-OMON26767.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NL-OMON26767.